文献速递产科

口服氢氯噻嗪联合赖诺普利与硝苯地平治疗产后高血压的比较效果初步随机对照试验

Oral combined hydrochlorothiazide and lisinopril vs nifedipine for postpartum hypertension: a comparative-effectiveness pilot randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol · 2023-02-12

该初步随机对照试验纳入产后72小时内需药物治疗的高血压患者70例,随机接受氢氯噻嗪联合赖诺普利或硝苯地平治疗。主要结局(产后7-10天家庭血压监测或再入院时2级高血压)在联合治疗组发生率为27%,硝苯地平组为43%(后验校正相对风险0.74,95%可信区间0.40-1.31)。贝叶斯分析显示联合治疗降低主要结局的後验概率为85%,但差异未达统计学显著,作者认为需更大规模试验确认。

要点

  • 联合氢氯噻嗪和赖诺普利组主要结局发生率为27%,硝苯地平组为43%。
  • 后验校正相对风险为0.74(95%可信区间0.40-1.31),差异未达统计学显著。
  • 贝叶斯分析显示联合治疗降低主要结局的後验概率为85%。

核心结论

  • 初步试验结果提示,与硝苯地平相比,氢氯噻嗪联合赖诺普利治疗有高概率产生更优的短期血压控制,但需更大规模试验确认。

研究设计与样本

  • 初步随机对照试验,于2021年10月至2022年6月进行,纳入慢性高血压或妊娠期高血压疾病患者,要求产后72小时内有2次收缩压≥150毫米汞柱和/或舒张压≥100毫米汞柱。
  • 按诊断(慢性高血压 vs 妊娠期高血压疾病)分层后随机分配至氢氯噻嗪联合赖诺普利组或硝苯地平组。
  • 计划样本量为70例,实际111例符合条件者中70例(63%)同意并随机分组(氢氯噻嗪联合赖诺普利组31例,硝苯地平组36例;随机后3例撤回知情同意)。
  • 主要结局为产后7至10天家庭血压监测或因血压控制再入院时发现的2级高血压(收缩压≥140毫米汞柱和/或舒张压≥90毫米汞柱)。
  • 采用意向性分析计算相对风险及95%可信区间,并进行预先计划的贝叶斯分析以估计获益或伤害概率。

主要发现

  • 主要结局在氢氯噻嗪联合赖诺普利组发生率为27%,在硝苯地平组为43%(后验校正相对风险0.74,95%可信区间0.40-1.31)。
  • 贝叶斯分析显示,相对于硝苯地平,氢氯噻嗪联合赖诺普利治疗降低主要结局的後验概率为85%。
  • 两组在次要结局或药物不良事件方面未见差异。
  • 主要结局数据有9例(12.8%)缺失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angiotensin-converting enzyme inhibitors and diuretics may be underutilized for postpartum hypertension because of their teratogenicity during pregnancy. OBJECTIVE: We evaluated whether combined oral hydrochlorothiazide and lisinopril therapy produced superior short-term blood pressure control when compared with nifedipine among postpartum individuals with hypertension requiring pharmacologic treatment. STUDY DESIGN: We performed a pilot randomized controlled trial (October 2021 to June 2022) that included individuals with chronic hypertension or hypertensive disorders of pregnancy with 2 systolic blood pressure measurements ≥150 mm Hg and/or diastolic blood pressure measurements ≥100 mm Hg within 72 hours after delivery. Participants were randomized to receive either combined hydrochlorothiazide and lisinopril therapy or nifedipine therapy after stratifying the participants by diagnosis (chronic hypertension vs hypertensive disorders of pregnancy). The primary outcome was stage 2 hypertension (systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg) determined using a home blood pressure monitor on days 7 to 10 after delivery or at readmission to the hospital for blood pressure control. The secondary outcomes included severe maternal morbidity (any of the following: intensive care unit admission; hemolysis, elevated liver enzymes, low platelet count syndrome; eclampsia; stroke; cardiomyopathy; or maternal death), need for intravenous medications after randomization, hospital length of stay, blood pressure during first clinic visit, medication compliance, and adverse events. A pilot trial with 70 individuals was planned given the limited available data on combined hydrochlorothiazide and lisinopril therapy use in postpartum care. We calculated relative risks and 95% credible intervals in an intention-to-treat analysis. Finally, we conducted a preplanned Bayesian analysis to estimate the probability of benefit or harm with a neutral informative prior. RESULTS: Of 111 eligible individuals, 70 (63%) agreed and were randomized (31 in the hydrochlorothiazide and lisinopril group and 36 in the nifedipine group; 3 withdrew consent after randomization), and the characteristics were similar at baseline between the groups. The primary outcome was unavailable for 9 (12.8%) participants. The primary outcome occurred in 27% of participants in the hydrochlorothiazide and lisinopril group and in 43% of the participants in the nifedipine group (posterior adjusted relative risk, 0.74; 95% credible interval, 0.40-1.31). Bayesian analysis indicated an 85% posterior probability of a reduction in the primary outcome with combined hydrochlorothiazide and lisinopril therapy relative to nifedipine treatment. No differences were noted in the secondary outcomes or adverse medication events. CONCLUSION: The results of the pilot trial suggest a high probability that combined hydrochlorothiazide and lisinopril therapy produces superior short-term BP control when compared with nifedipine. These findings should be confirmed in a larger trial.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Fishel Bartal M, Blackwell SC, Pedroza C, et al. Oral combined hydrochlorothiazide and lisinopril vs nifedipine for postpartum hypertension: a comparative-effectiveness pilot randomized controlled trial. Am J Obstet Gynecol. 2023. PMID: 36787814. doi:10.1016/j.ajog.2023.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。